Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19

Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19

MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blin...

Full description

Saved in:
Bibliographic Details
Main Authors: Hye Sung Han, Won-Serk Kim, Yangwon Lee, Chong-Hyun Won, Wooshun Lee, Sun Young Choi, Beom Joon Kim
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Toxins
Subjects:
glabellar lines
botulinum toxin A
MBA-P01
coronavirus disease
Online Access:https://www.mdpi.com/2072-6651/17/4/160
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2072-6651/17/4/160

Similar Items